UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stock Position in Johnson & Johnson (NYSE:JNJ)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 8.0% during the third quarter, Holdings Channel reports. The institutional investor owned 16,576,212 shares of the company’s stock after selling 1,436,136 shares during the quarter. Johnson & Johnson accounts for 0.7% of UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings, making the stock its 19th largest holding. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Johnson & Johnson were worth $2,686,341,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Strategic Wealth Partners Ltd. boosted its holdings in Johnson & Johnson by 26.7% in the 1st quarter. Strategic Wealth Partners Ltd. now owns 6,077 shares of the company’s stock worth $961,000 after buying an additional 1,280 shares during the period. Raelipskie Partnership lifted its position in shares of Johnson & Johnson by 3.9% during the first quarter. Raelipskie Partnership now owns 14,090 shares of the company’s stock worth $2,229,000 after acquiring an additional 531 shares in the last quarter. Community Trust & Investment Co. grew its position in shares of Johnson & Johnson by 0.9% in the first quarter. Community Trust & Investment Co. now owns 96,066 shares of the company’s stock valued at $15,197,000 after purchasing an additional 877 shares in the last quarter. Cetera Investment Advisers raised its stake in shares of Johnson & Johnson by 224.0% during the 1st quarter. Cetera Investment Advisers now owns 707,273 shares of the company’s stock valued at $111,884,000 after purchasing an additional 488,955 shares during the period. Finally, Cetera Advisors LLC lifted its holdings in Johnson & Johnson by 71.6% during the 1st quarter. Cetera Advisors LLC now owns 274,630 shares of the company’s stock worth $43,444,000 after purchasing an additional 114,547 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on JNJ. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Citigroup raised their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Royal Bank of Canada upped their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Morgan Stanley lifted their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Wolfe Research started coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Seven research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $175.94.

Johnson & Johnson Stock Up 0.6 %

Shares of JNJ opened at $155.39 on Thursday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The stock has a 50 day simple moving average of $159.52 and a two-hundred day simple moving average of $156.38. The firm has a market cap of $374.12 billion, a P/E ratio of 22.49, a P/E/G ratio of 2.77 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.66 EPS. On average, analysts forecast that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.19%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This represents a 22.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.